OncoSpherix is pleased to announce that it was selected for the investor pitch portion of the annual AdvanSE conference that is being held in Charleston, SC, October 27-29, 2021. The AdvanSE conference is an annual event for Southeast Life Sciences (SELS), an organization that joins life science organizations from 7 states in the region and whose mission is to “cultivate, convene, and connect the Southeast entrepreneurial ecosystem to foster the public good and life science innovation & investment across the region”. SELS is the result of a recent merger of Southeast Medical Device Association (SEMDA) and SEBIO.
OncoSpherix’s CEO, Margaret K. Offermann, M.D., Ph.D., will present on October 28th, 2021, at 10:45am ET, sharing information on the company’s progress and plans for advancing its small molecule dual HIF-1 and HIF-2 inhibitors as part of combination therapy for attacking unresectable and aggressive solid cancers. OncoSpherix is embarking on a Series A fundraising round of $25M that will take its clinical lead 64B through Phase II clinical trials.